[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,709,637
  • Shares Outstanding, K 64,311
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -130,150 K
  • EBIT $ -142 M
  • EBITDA $ -147 M
  • 60-Month Beta 1.79
  • Price/Sales 189.29
  • Price/Cash Flow N/A
  • Price/Book 13.29

Options Overview Details

View History
  • Implied Volatility 66.43% (+0.05%)
  • Historical Volatility 43.46%
  • IV Percentile 97%
  • IV Rank 92.14%
  • IV High 69.06% on 07/13/26
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 28) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 50
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 7,463
  • Open Int (30-Day) 7,428
  • Expected Range 135.48 to 135.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.11
  • Number of Estimates 3
  • High Estimate $2.54
  • Low Estimate $1.61
  • Prior Year $-0.55
  • Growth Rate Est. (year over year) +483.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.27 +14.92%
on 06/29/26
143.29 -5.15%
on 07/20/26
+13.76 (+11.26%)
since 06/24/26
3-Month
92.75 +46.53%
on 06/02/26
143.29 -5.15%
on 07/20/26
+35.91 (+35.91%)
since 04/24/26
52-Week
50.49 +169.21%
on 08/08/25
143.29 -5.15%
on 07/20/26
+82.17 (+152.90%)
since 07/24/25

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 136.44 (+0.75%)
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks. PTGX holds a 100% “Buy” technical opinion from Barchart. Despite bullish analyst sentiment...

PTGX : 136.44 (+0.75%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 136.44 (+0.75%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 136.44 (+0.75%)
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will...

PTGX : 136.44 (+0.75%)
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer,...

PTGX : 136.44 (+0.75%)
Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics: Q1 Earnings Snapshot

PTGX : 136.44 (+0.75%)
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible...

PTGX : 136.44 (+0.75%)
PTGX: The Partnership Everyone's Celebrating Might Be the Problem

Barchart Research What to Expect from PTGX Earnings PTGX Generated May 4, 2026 Current Price $99.52 EPS Estimate $$-0.65 Consensus Rating Strong Buy Average Move 3.25% PTGX: The Partnership Everyone's...

PTGX : 136.44 (+0.75%)
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera

PTGX : 136.44 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 143.16
2nd Resistance Point 140.24
1st Resistance Point 137.84
Last Price 136.44
1st Support Level 132.51
2nd Support Level 129.59
3rd Support Level 127.19

See More

52-Week High 143.29
Last Price 136.44
Fibonacci 61.8% 107.84
Fibonacci 50% 96.89
Fibonacci 38.2% 85.94
52-Week Low 50.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.